UTHR
United Therapeutics Corporation
$414.73
-$2.84(-0.68%)
65
Overall
80
Value
50
Tech
--
Quality
Market Cap
$18.89B
Volume
670.91K
52W Range
$266.98 - $436.95
Target Price
$468.83
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $1.5B | $1.6B | $1.7B | $1.6B | $1.4B | $1.5B | $1.7B | $1.9B | $2.3B | $2.9B | ||
| Total Revenue | $1.5B | $1.6B | $1.7B | $1.6B | $1.4B | $1.5B | $1.7B | $1.9B | $2.3B | $2.9B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-69.0M | $-72.7M | $-105.7M | $-198.7M | $-117.6M | $-108.1M | $122.5M | $151.6M | $257.5M | $309.7M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $1.4B | $1.5B | $1.6B | $1.2B | $995.0M | $1.4B | $1.6B | $1.8B | $2.1B | $2.6B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $697.8M | $464.4M | $804.7M | $357.9M | $1.2B | $357.7M | $540.1M | $805.0M | $885.1M | $1.2B | ||
| Research & Development | $245.1M | $147.6M | $264.6M | $357.9M | $1.2B | $357.7M | $540.1M | $322.9M | $408.0M | $481.0M | ||
| Research Expense | $245.1M | $147.6M | $264.6M | $357.9M | $1.2B | $357.7M | $540.1M | $322.9M | $408.0M | $481.0M | ||
| Selling, General & Administrative | $452.7M | $316.8M | $330.1M | $265.8M | -- | -- | -- | $482.1M | $477.1M | $709.7M | ||
| Selling & Marketing Expenses | $452.7M | $316.8M | $330.1M | $265.8M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-3.8M | $-4.4M | $-4.8M | $-4.2M | $-4.9M | $-3.5M | -- | $482.1M | $477.1M | $709.7M | ||
| Salaries & Wages | $-280.3M | $-12.1M | $-73.5M | $-700.0K | $-45.4M | $-163.8M | $5.0M | $5.0M | $-1.4M | $-1.8M | ||
| Depreciation & Amortization | $-31.8M | $-31.0M | $-30.5M | $-35.8M | $-45.7M | $-49.7M | $49.8M | $51.2M | $52.9M | $71.6M | ||
| Depreciation & Amortization | $-31.8M | $-31.0M | $-30.5M | $-35.8M | $-45.7M | $-49.7M | $49.8M | $51.2M | $52.9M | $71.6M | ||
| Amortization | $-1.1M | $-600.0K | $-500.0K | $-100.0K | $-200.0K | $-200.0K | $28.0M | $28.0M | $29.5M | $27.1M | ||
| Other Operating Expenses | -- | -- | $210.0M | -- | -- | $-700.0K | $-5.8M | $-19.7M | $-2.2M | $-8.7M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $699.0M | $1.1B | $814.9M | $805.4M | $-187.6M | $593.6M | $555.9M | $979.7M | $1.2B | $1.4B | ||
| EBITDA | $1.1B | $1.1B | $809.5M | $808.7M | $-74.9M | $712.3M | $662.4M | $1.0B | $1.3B | $1.6B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $4.7M | $3.9M | $9.0M | $13.9M | $44.2M | $23.5M | $18.6M | $32.4M | $59.3M | -- | ||
| Intinc | -- | -- | $-38.7M | $-24.9M | $44.2M | $28.6M | $16.7M | $45.2M | $162.7M | $199.1M | ||
| Net Non-Operating Interest Income/Expense | $-4.7M | $-3.9M | $-47.7M | $-38.8M | -- | $5.1M | $-1.9M | $12.8M | $162.7M | $199.1M | ||
| Gain on Sale of Securities | -- | -- | $-49.6M | -- | -- | $3.4M | $92.6M | $900.0K | -- | -- | ||
| Other Income/Expense | $-350.1M | $-2.4M | $-2.3M | $7.7M | $-22.6M | $-40.2M | $-39.9M | $-41.9M | $14.0M | $-5.8M | ||
| Other Special Charges | $100.0K | $2.4M | $2.3M | $-7.7M | $22.6M | $49.3M | $42.2M | $-40.2M | $-14.0M | $5.8M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-54.2M | $-36.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $54.2M | $36.0M | -- | -- | $17.2M | $5.4M | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | $-17.2M | $-5.4M | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $1.0B | $1.1B | $778.5M | $772.8M | $-120.8M | $662.4M | $612.5M | $983.0M | $1.3B | $1.5B | ||
| Pre-Tax Income | $1.0B | $1.1B | $769.5M | $758.9M | $-165.0M | $638.9M | $593.9M | $950.6M | $1.3B | $1.5B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $392.8M | $346.5M | $351.6M | $169.7M | $-60.5M | $124.1M | $118.1M | $223.3M | $289.5M | $343.9M | ||
| NET INCOME | ||||||||||||
| Net Income | $651.6M | $713.7M | $417.9M | $589.2M | $-104.5M | $514.8M | $475.8M | $727.3M | $984.8M | $1.2B | ||
| Net Income (Continuing Operations) | $651.6M | $713.7M | $417.9M | $589.2M | $-104.5M | $514.8M | $475.8M | $727.3M | $984.8M | $1.2B | ||
| Net Income (Discontinued Operations) | $651.6M | $713.7M | $417.9M | $589.2M | $-104.5M | $514.8M | $475.8M | $727.3M | $984.8M | $1.2B | ||
| Net Income (Common Stockholders) | $651.6M | $713.7M | $417.9M | $589.2M | $-104.5M | $514.8M | $475.8M | $727.3M | $984.8M | $1.2B | ||
| Normalized Income | -- | -- | -- | -- | $-242.7M | $508.4M | -- | -- | -- | $1.5B | ||
| TOTALS | ||||||||||||
| Total Expenses | $628.8M | $391.7M | $699.0M | $159.2M | $1.1B | $249.6M | $662.6M | $956.6M | $1.1B | $1.5B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $46.0M | $43.8M | $44.0M | $43.5M | $43.8M | $44.2M | $44.9M | $45.5M | $46.8M | $45.2M | ||
| Average Shares Outstanding (Diluted) | $51.2M | $46.8M | $44.9M | $44.0M | $43.8M | $44.6M | $47.3M | $48.5M | $49.7M | $48.5M | ||
| Shares Outstanding | $45.4M | $45.0M | $43.2M | $43.7M | $43.9M | $44.5M | $45.1M | $46.3M | $47.1M | $44.9M | ||
| Basic EPS | $14.17 | $16.29 | $9.5 | $13.54 | $-2.39 | $11.65 | $10.6 | $15.98 | $21.04 | $26.44 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $10.6 | $15.98 | $21.04 | $26.44 | ||
| Diluted EPS | $12.72 | $15.25 | $9.31 | $13.39 | $-2.39 | $11.54 | $10.06 | $15 | $19.81 | $24.64 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $10.06 | $15 | $19.81 | $24.64 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | $350.0M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Interest Expense Operating | $-4.7M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $-3.8M | $-4.4M | $-4.8M | $-4.2M | $-4.9M | $-3.5M | -- | $482.1M | $477.1M | $709.7M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $9.1M | $2.3M | $1.7M | -- | -- | ||
| Rent And Landing Fees | $-3.8M | $-4.4M | $-4.8M | $-4.2M | $-4.9M | -- | -- | -- | -- | -- | ||
| Selling Expense | $452.7M | $316.8M | $330.1M | $265.8M | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | $-57.6M | -- | -- | -- | -- | -- | ||
| Restruct | $-54.2M | $-36.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | UTHR | $414.73 | -0.7% | 670.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get United Therapeutics Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW